<DOC>
	<DOCNO>NCT02861651</DOCNO>
	<brief_summary>Acute erythroid leukemia ( AEL ) morphologically distinct , infrequent ( o5 % ) acute myeloid leukemia ( AML ) design M6 French- American-British ( FAB ) classification . The World Health Organization classification recognize two subclass , M6a , leukemia myeloid blast cell , M6b , rare , purely erythroid AML . It may difficult distinguish myelodysplastic syndrome AEL erythroblastic proliferation , increase dysplasia present . No recurrent cytogenetic abnormality specific AEL prognosis poor median survival 17 month . A study 14 gene series 92 case show mutation frequent AEL somewhat differ AMLs low high proportion FLT3-ITD TP53 mutation , respectively . Only three case AEL report TCGA database . To characterize AEL , determine whether constitutes distinct class AML document reason poor prognosis , investigator search molecular alteration 40 M6a-AMLs use array comparative genomic hybridization ( aCGH ) next-generation sequencing ( NGS ) 106 gene know suspected role myeloid malignancy erythrocyte differentiation .</brief_summary>
	<brief_title>Molecular Characterization Acute Erythroid Leukemia ( M6-AML ) Using Targeted Next-generation Sequencing</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Age &gt; 18 year Diagnosis AML6 Written consent obtain No write consent No frozen sample</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>